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Introduction
Important medical advances over the last several
decades have vastly improved the technical capacity
to control human pain. Millions of patients suffering
from cancer, HIV/AIDS, and other conditions have
been able to find relief from incapacitating chronic
and acute pain. However, despite these developments,
pain remains severely under treated worldwide, particularly in developing countries. The tragic consequence is that for millions of people around the globe,
excruciating pain is an inescapable reality of life.
Medical availability of effective pain medication
is undoubtedly one of the most neglected realms of
global public health. Over the last few years, public
and scholarly attention has centered on the important issue of access to medicines, particularly in the
context of HIV/AIDS antiretroviral therapy (ARV).
Unfortunately, the global attention to ARV therapy
has not stimulated broader attention to the universal
issue of human pain that plagues millions of persons
around the globe with terminal, chronic, and acute
conditions. The lack of pain management options for
marginalized populations is an enduring and expanding global health calamity.
The failure of national governments to prioritize
access to opioid analgesics for pain, and the complex
socioeconomic, cultural, and regulatory factors contributing to the underutilization of pain medicine in
developing countries, are widely documented.1 Notably, however, there has been no scholarly consideration of the global drug regulatory environment or
how international law and international institutions
either interfere with or can contribute to national
efforts to strengthen pain management. Opium is not
only integral to the relief of individual pain, but it is
also an internationally regulated substance under the
1961 United Nations Single Convention on Narcotic
Drugs (Single Convention).2
The goals of this article are twofold: (1) to critically
analyze the impact of the international drug regulatory regime on medical availability of narcotic drugs
and (2) to consider legal and institutional mechanisms
that can be employed globally to promote wider accessibility of these critical medicines. The United Nations
international drug control regime, including the Single
Allyn L. Taylor, J.D., LL.M., J.S.D., is a Visiting Professor of Law at the O’Neill Institute for National and Global
Health Law at Georgetown University Law Center and an
Adjunct Professor of International Relations at the Paul H.
Nitze School of Advanced International Studies at Johns Hopkins University. She has been a Health Policy Adviser at the
World Health Organization in Geneva, Switzerland and a
Legal Consultant to the WHO Department of Medicines Policy
and Standards.

556

journal of law, medicine & ethics

Allyn L. Taylor

Convention and the international organizations that
support it, is traditionally understood to focus on the
criminalization of drug abuse. It typically has not been
regarded as a mechanism to provide a global framework to advance medical availability of opioids. However, ensuring medical availability of narcotic drugs
for medicinal purposes constitutes a key but neglected
aim of the international legal regime. This article con-

wide6 – countries in which the need for pain medicine
is large and growing. Of the 57 million people who die
annually, approximately six million deaths are from
cancer and three million are from HIV/AIDS, with
the majority of such deaths occurring in developing
states.7 Notably, the majority of people lacking access
to opioid analgesics have a heightened need for such
medication because of a relative lack of access to cura-

While morphine and other opioid analgesics are largely available in the United
States, Western Europe, Australia, and New Zealand, they are in critically
short supply in developing countries, newly industrializing countries, and
formerly socialist states. Poor countries, which comprise about 80 percent
of the world’s population, account for only about six percent
of global consumption of morphine.
tends that a more balanced approach to international
implementation of the Single Convention on Narcotic
Drugs – one that weighs the Convention’s dual goals
of controlling abuse and ensuring availability – can
have an important, albeit limited, influence on states
in encouraging medical availability of opioids.

Pain and Pain Management in Global
Perspective
Today we have the knowledge to provide highly effective pain relief to improve the quality of life and conditions of death for millions of people suffering from
cancer, HIV/AIDS, chronic conditions, post-surgical
pain, and other agonizing illnesses. Tragically, however, only a small percentage of the world’s population
that could benefit from pain relief has access to such
services. According to the World Health Organization
(WHO), 80 percent of persons worldwide suffering
from severe pain do not receive adequate treatment.3
Despite the global scale of the human suffering
caused by lack of access to morphine and other opioid analgesics, many countries have yet to recognize
pain management as an important public health concern. While morphine and other opioid analgesics are
largely available in the United States, Western Europe,
Australia, and New Zealand, they are in critically
short supply in developing countries, newly industrializing countries, and formerly socialist states.4 Poor
countries, which comprise about 80 percent of the
world’s population, account for only about six percent
of global consumption of morphine.5
WHO estimates that severe under treatment for pain
is an acute problem in more than 160 countries worldglobal health law, ethics, and policy • winter 2007

tive or palliative care, such as surgery, chemotherapy,
radiotherapy, or anti-retroviral drugs in poor states.8
Millions of others suffering from moderate to severe
pain from other causes, including chronic illnesses
such as diabetes, heart disease, and lung disease, also
receive no pain management.
Pain control is designed to minimize physical discomfort and allow patients to function normally. There
are a number of different interventions for pain relief,
including drugs and radiotherapy, as well as anesthetic, neurosurgical, psychological, and behavioral
approaches. However, morphine and other opioid
analgesics are the only effective analgesia for a wide
variety of conditions, including cancer pain, chronic
pain, diabetic neuropathy, HIV neuropathy, sickle cell
disease, surgical pain, and traumatic pain.9 Morphine
has also been recognized by WHO as an essential
medicine since the elaboration of the first Model List
of Essential Medicines in 1977.10
The importance of opioids as analgesic medication
for the management of moderate and severe pain is
well understood. Significant advances in pharmacology and technology over the last several decades have
improved our capacity to control pain. Although the
field of pain management is still evolving, the development of well-crafted protocols has brought relief to the
suffering of millions and allowed persons with terminal illnesses to die in relative comfort.11 Opioid analgesics have been recognized by WHO as absolutely safe,
effective, and essential for the management of cancer
pain.12 Research has shown that WHO’s three-step
model analgesic method for cancer pain relief is effective in 90 percent of cancer patients.13
557
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In the future, the global need for pain medicine will
increase rapidly. In developed and developing countries, the world’s population is aging, resulting in an
increase of the prevalence of chronic, painful conditions and cancer. By 2025, there will be 1.2 billion
people over the age of 60, which is double the current
estimate of 600 million.14 Future demand for such
care is also expected to rise due to the dramatically
expanding prevalence of HIV/AIDS in several parts of
the world. Tragically, the greatest need for pain relief
is increasingly concentrated in developing countries,
where access to morphine and other opioid analgesics
is inadequate or non-existent. For example, WHO estimates that the burden of cancer will increasingly shift
from industrialized countries to developing states, so
that by the year 2020, 70 percent of the estimated
20 million new cancer cases will occur in developing
states.15
In order to address the global challenge of managing pain, vastly strengthened national and international action is necessary. In the absence of more
effective approaches to pain management, WHO estimates that 600 million people alive today will experience negative health impacts during their lifetime as a
result of the inability to obtain access to effective pain
medicine.16
National Challenges to Medical Availability
Improving quality of life and the circumstances surrounding death and dying through equitable access
to pain management requires an appreciation of the
multiple barriers that exist, nationally and internationally, to providing analgesics. At the national level,
a number of complex socio-economic, cultural, ethical, and political factors coalesce to generate substandard conditions for pain management.17
In developing nations, pain management must be
understood within the context of underlying conditions of poverty and underdevelopment. Basic pain
management must compete for scarce resources and
political attention with other primary health care
services as well as with other social concerns, such
as education, food, and transportation.18 Poverty and
underdevelopment affect both national health policies as well as individual access to pain services. In
developing nations, opioid availability is typically limited to specialty centers; opioids are largely delivered
parenterally to hospitalized patients, and dispensation is restricted to a select group of health care providers.19 Additionally, economic factors merge with
demographic and geographical barriers to further
obstruct availability of medicinal opium. For example,
patients who cannot afford medication, or who are
unable to travel to centers designated for treatment,
558

are excluded from care. In many countries, over half of
the population will never encounter a nurse or doctor
in their lifetime.20
The economic, demographic, and geographical
obstacles to pain management are compounded by
the inflated costs of opioid analgesics in developing
nations. Morphine is a low-cost, effective pain relief
medicine ideally suited for poor countries. It is inexpensive to manufacture, costing approximately one
American cent for each ten milligrams of generic
morphine sulfate tabulate or morphine hydrochloride solution.21 Thus, unlike the global political battle
over access to antiretroviral medicine for HIV/AIDS
that has dominated public debates during this decade,
patents and pricing should not be a major barrier to
opioid availability. However, pharmaceutical companies often supply more expensive opioid formulations
in developing countries, thus limiting their capacity
to obtain cheap oral morphine.22 Ironically, research
indicates that the cost of pain medication in developing countries exceeds the cost in industrialized
states.23
In addition to economic factors, cultural attitudes
and knowledge barriers contribute to the under treatment of severe pain.24 The notion that individual pain
is a private matter to be endured without complaint
is widely held.25 This attitude of silent suffering can
be compounded by cultural and ethnic differences
among patients and providers. These differences can
create communication gaps and cultural barriers,
which impede the recognition and treatment of severe
pain.
Furthermore, in many cultures, patients hold an
irrational fear that opioid addiction will result from use
during appropriate pain management. Research has
soundly established that addiction is rare after using
a powerful opioid analgesic for a legitimate medical
purpose and that opioid analgesics are a core component of good clinical practice. In short, the medical use
of opioids does not create addicts, while undue limitations on medical use of opioids hurts patients.26 However, the mistaken link between addiction and medical
usage of opioid analgesics persists.
Similarly, a lack of training and basic education in
the use of opioids has also created an irrational fear of
addiction or misuse of opioid analgesics among health
care professionals. This problem is found in both
industrialized and developing countries and usually
leads to the under treatment of pain.27 Consequently, it
is widely recognized that integration of pain management training in the undergraduate and continuing
education of doctors, nurses, and other allied health
professionals in nations worldwide is a critical factor
in efforts to widen pain treatment worldwide.28
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Perhaps the most important national barrier to the
access to opioid analgesics is the absence of government commitment, including the commitment to
encourage or facilitate availability and appropriate
education of health care professionals. In resourcelimited settings, medical availability of opioids is often
considered a low clinical and political priority. Pain
relief for the terminally, critically, and chronically ill
must compete for limited resources against programs
aimed at the prevention and treatment of disease in
the young and healthy. Consequently, funds allotted
for medical availability of opioids are often limited.29
Many governments in developing countries do not
recognize palliative care, including access to opioid
analgesics to relieve suffering, as a national health care
priority. The absence of political will to support effective pain management is evidenced by the fact that
only a handful of poor countries have implemented
WHO’s recommendation to adopt a national policy
that integrates palliative care into the existing health
system. In Africa, for example, Uganda was the only
country in 2002 to prioritize palliative care, including
access to pain medication for persons with HIV/AIDS
and cancer, in its national health plan.30
The absence of political will to support the availability of pain relief medication is also evident in the overregulation of medicinal opium, an unremitting and
critical problem that interferes with the availability of
powerful analgesics in many poor countries.31 Governments worldwide hold a legitimate concern about the
diversion of licit medicines into illegal channels. In
many countries, however, the regulatory response has
not been narrowly tailored to ensure that concerns of
law enforcement do not unduly interfere with medical availability. As a consequence, opioid distribution
is so tightly regulated that it can become too burdensome or difficult for health care providers to offer their
patients effective pain control. Overwhelming prescription-filing requirements, inappropriate restrictions on the amount and duration of prescriptions,
and other practices that interfere with clinical practice
are common. For example, in India, a health facility
planning on dispensing opioids must scale a number
of cumbersome and time-consuming regulatory hurdles. It must obtain an opioid possession license, as
well as government license forms for opioid purchase,
transport, and import, in order to legally dispense it.32
To further compound the difficulties of access, prescriptions for oral morphine cannot, by law, be filled
at commercial pharmacies. Only a limited number of
tertiary and cancer hospitals hold such licenses, so that
consequently, the vast majority of rural inhabitants in
India do not have access to effective pain relief.33 In
Kerala, an Indian state of over 30 million people, only
global health law, ethics, and policy • winter 2007

three major health facilities dispense oral morphine.34
Although much of the world’s supply of morphine
comes from India, overregulation means that only a
trickle of the production is made available to patients
there.35
The failure of governments to prioritize access to
opioid analgesics and the complex national socioeconomic, cultural, and regulatory factors contributing to
the underutilization of pain medicine in developing
countries are widely understood. A number of organizations, including WHO and the Pain and Policy
Studies Group, a WHO collaborating center, work
with countries to improve the policy environment for
treating patients with pain. In February 2007, WHO
substantially increased its commitment to advance the
medical availability of opioid analgesics by launching
a new program designed to support national efforts in
ensuring adequate availability of opioid analgesics for
pain treatment for their populations.36 The new WHO
Access to Controlled Medications Programme will
work with states to address a number of the critical
national factors that interfere with medical availability. Among other things, this programme will include
the following: (1) review of relevant national legislation and administrative procedures; (2) promotion
of continuing medical education and rational use of
controlled medications by health care professionals;
and (3) assistance in ensuring an uninterrupted supply of opioid analgesics at affordable prices. Given the
scope of the global public health concern, it is critical to enhance the technical and regulatory capacity
of governments in order to advance medical availability of opioid analgesics. Innovative and strengthened
approaches to advance patient access to pain medicine
are urgently needed.

The Impact of International Law and
Institutions on the Medical Availability
of Opioids
While important advances have been made in identifying the national regulatory factors that impede
access to pain medication, the impact of the international regulatory environment on medical availability
of opioid analgesics, and the global mechanisms that
can be adopted to promote national efforts to provide
effective pain medicine, have thus far received limited
scholarly and public attention. Morphine and other
opioid analgesics are not only central to pain management, they are also controlled substances under a
complex United Nations drug regulatory regime. As
described herein, the regulatory scheme established
by the United Nations drug control regime substantially interferes with the capacity of states to broaden
drug availability for legitimate public health purposes.
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Reconceptualizing the drug control regime in a broader
public health context may make an important contribution to efforts to advance pain relief worldwide.
The International Legal Framework for
Narcotics Control
International drug control, including the control of
opium, was one of the earliest fields of international
cooperation. Crude opium has been available for
thousands of years, but with the expansion of British opium trade in Asia in the 18th and 19th centuries and the development of the hypodermic syringe
in the late 1860s, the abuse of opioids rose dramatically. By the late 19th century, global concern with
opium consumption and trade reached a critical juncture, which led to public and professional pressure
to restrict medical access to opioids for pain relief.
These circumstances provided the backdrop for the
first international cooperative arrangements for drug
control that began to emerge in the early part of the
20th century.37 In 1909, the first International Opium
Commission was convened in Shanghai, China, and it
served as the platform for the first international legal
instrument regulating psychoactive substances, the
Hague Opium Convention of 1912.
The multilateral drug control regime has evolved
over the last hundred years into a highly complex regulatory morass involving multiple treaties and international organizations. The scope of control over drugs
has also broadened and deepened over time, both substantively and conceptually. Substantively, the list of
drugs regulated has grown to include not just opium
and cocaine, but also a range of newer psychotropic
substances. Conceptually, the goals of the regime have
shifted from an initial focus on the regulation and
trade of drugs with legitimate medical purposes to a
more recent emphasis on fostering multilateral cooperation to address the problems associated with licit
and illicit drug abuse.38
The key multilateral drug conventions in force
today are the 1961 United Nations Single Convention
on Narcotic Drugs, the 1971 United Nations Convention on Psychotropic Substances, and the 1988 United
Nations Convention Against the Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The centerpiece of United Nations drug control regime, and
of particular importance to the global availability of
powerful opioid analgesics, is the Single Convention,
which regulates narcotics including morphine and
drugs with similar effects. The treaty regime has been
remarkably influential in standardizing national drug
laws, with some important exceptions, particularly in
the realm of “harm reduction” efforts discussed below.
As of 2005, 183 nations are party to the Single Con560

vention,39 while other states and territories that are
not formally party to the instrument comply with its
terms,40 leaving only a handful of states outside the
reach of the global drug regulatory ambit.
The twin aims of the Single Convention, as specified in its preamble and text, are to control the use and
trafficking of substances with abuse potential while
assuring the availability of these drugs for scientific
and medical purposes. Assuring availability of drugs
for scientific and medical purposes is of first importance in the text of the 1961 Single Convention.41 As
described below, the Convention sets forth detailed
obligations for State Parties and relevant international organizations to limit exclusively to medical
and scientific purposes the production, manufacture,
export, import, distribution, trade, use, and possession of drugs in order to achieve the core aims of the
instrument.
The Single Convention emphasizes plant-based
drugs such as opium, heroin, cannabis, and cocaine
and classifies narcotic drugs according to their danger to health, risk of abuse, and therapeutic value. It
establishes four schedules for controlled substances,
with Schedule 1, applicable to morphine and drugs
with similar effects and constituting the “standard
regime of the Single Convention.”42 Schedule 1 contains substances that are subject to all of the control
provisions of the treaty. Key features of the Schedule
1 treaty regime include the limitation to medical and
scientific purposes of all phases of narcotics trade
(manufacture, wholesale and retail domestic trade,
and international trade) and of the possession and use
of drugs.
The Single Convention seeks to control illicit
trade and abuse through stringent regulation of all
phases of the supply of drugs. Government authorization (licensing and state ownership) is mandatory
for participation in any phase of narcotics trade, and
each individual international transaction requires an
export or import license. A centerpiece of the Single
Convention is a global “estimates” system designed to
limit the total quantities of drugs, whether produced
domestically or imported, available in each country on
an annual basis, to that needed for medical and scientific purposes. The treaty also requires that every
participant keep detailed records of all transactions
in drugs and submit annual and quarterly statistical
reports.
A complex network of international organizations
and agencies has the responsibility of implementing
the treaty. Most importantly, Article 9 of the Single
Convention establishes the International Narcotics
Control Board (INCB) as the lead organ of the Single
Convention regime with the authority to monitor and
journal of law, medicine & ethics

Allyn L. Taylor

promote the application of the Single Convention by
State Parties.43 The 53-member Commission on Narcotic Drugs (CND) – the central drug policy making
body in the United Nations system that is an organ
of the Economic and Social Council (ECOSOC) – has
specific authority pursuant to the Single Convention
to add, remove, and transfer drugs among the treaty’s
four schedules of controlled substances. Any changes
by the CND to drug scheduling under the Single Convention must be made in accordance with the findings
and the recommendations of WHO. The CND may
also make recommendations to the INCB and nonparties in order to promote the implementation of the
Single Convention. Finally, the United Nations Office
on Drugs and Crime (UNODC), of which the INCB’s
Secretariat is a part, is charged with the day-to-day
responsibility of monitoring national compliance with
the treaty.
Public Health and the Prohibitionist Bias of the
Global Drug Control Regime
The international institutions that have collective
responsibility to implement the aims of the Single
Convention, the CND, the INCB, and UNODOC,
have emphasized a strict drug prohibitionist and
law enforcement approach to treaty interpretation
and application in an to effort bolster global action
to counter the extraordinary challenge of drug abuse
worldwide. The sheer size of the global public health
burden caused by drug trafficking and consumption is
daunting. Illicit drugs alone are estimated to be one of
the world’s largest trading sectors. At $400-$500 billion per year, illicit trafficking in narcotics constitutes
nearly ten percent of world trade and is larger than
the automobile market.44 The United Nations Office
on Drugs and Crime estimates that heroin is abused in
three-fourths of all countries, and cocaine is abused in
two-thirds.45 Drug trafficking has been linked to terrorism and organized crime, and drug-related problems include increased rates of crime and violence,
susceptibility to HIV/AIDS and hepatitis, and a breakdown in social behavior.46
Countering the global burden of drug abuse and
trafficking is an extraordinary global public health
challenge. However, the operation of the international
narcotics regime and, in particular, the strict prohibitionist approach of the international institutions
charged with implementing the aims of the Single
Convention, have been subject to a multiplicity of
criticisms. Numerous commentators, for example,
emphasize that the law enforcement approach to drug
abuse has, in fact, failed to curb abuse and illicit trafficking.47 Illicit drug abuse was a public health concern
in about 20 to 30 states when the Single Convention
global health law, ethics, and policy • winter 2007

was adopted in 1961. Today, 46 years after the adoption of the treaty and the establishment of the contemporary regime for global control, illicit drug abuse has
skyrocketed worldwide, with the total number of drug
abusers between the ages of 15 and 64 estimated to be
around 200 million.48
Critics of the global drug control regime also posit
that the traditional criminal justice approach to drug
control (emphasized by the United Nations agencies)
is at odds with the contemporary public health practice aimed at reducing drug abuse and its adverse consequences. In particular, observers argue that focusing the principal goal of drug policy on prohibition has
diverted attention away from treatment and towards
punishment. Countries such as Brazil, Canada, New
Zealand, Australia, and member states of the European
Union increasingly favor a “harm reduction” approach
to drug abuse, including the use of injecting rooms,
needle/syringe exchange programs, individual possession of cannabis for medical purposes, and substitution or maintenance treatment. However, the shift in
priorities to “harm reduction” is increasingly seen by
the INCB as covertly undermining prohibition. The
polarized debate between the INCB, with its prohibitionist, criminalization perspective, and those governments wishing to pursue a “harm reduction” approach
to drug control, is aired yearly at the annual meeting
of the INCB.49 Although State Parties argue that such
practices are consistent with the international law, the
INCB, in its annual report, frequently criticizes such
public health practices as conflicting with the letter
and the spirit of the Single Convention.50
Although it has received highly limited public and
media attention, the strict criminal justice approach
to treaty interpretation and application advanced by
the global drug agencies also impinges significantly
on the legal and political capacity of states to ensure
access to pain medication for legitimate medical purposes. As described above, enhancing medical availability of opioids is one of the twin goals of the Single
Convention along with the control of drug abuse. The
preamble of the Single Convention recognizes that “the
medical use of narcotic drugs continues to be indispensable for the relief of pain and suffering and that
adequate provision must be made to ensure the availability of narcotic drugs for such purposes.”51 Medical
availability of controlled substances is also a general
obligation of the State Parties. Article 4(c) provides
that Parties shall undertake legislative and administrative measures to “limit exclusively to medical and
scientific purposes the production, manufacture,
export, import, distribution of, trade in, use and possession of drugs.”52 Medical availability of morphine
and other opioid analgesics is, therefore, a cardinal
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aim of the Single Convention and a core obligation of
the Parties.
Implementing the aims of the Single Convention,
including ensuring medical availability of morphine
and other opioid analgesics, is a principal responsibility of the INCB. The INCB is mandated pursuant to
Article 9(4) to cooperate with State Parties to “limit
the cultivation, production, manufacture and use of
drugs to an adequate amount required for scientific
and medical purposes, to ensure their availability for
such purposes and to prevent illicit cultivation, pro-

scheduling of narcotics under the Single Convention.
Pursuant to Article 3, the Single Convention establishes a unique and expeditious international legal
process for adding a substance or changing the status
of a substance under the treaty’s four schedules without requiring a formal amendment to the Convention.
First, the Single Convention authorizes WHO to conduct a medical and scientific review of a substance and
to make a scheduling recommendation to the Commission on Narcotic Drugs. Second, the CND has the
final decision to schedule the substance, but may do so

Concerned that legitimate medicines can be diverted into illicit channels, the
International Narcotics Control Board has prioritized strict regulation
of opioid analgesics in policy and practice. This has, concomitantly, relegated
issues of medical availability to secondary consideration. Consequently, the
INCB has not advanced any interpretation or application of the
Single Convention in a manner that fulfills its obligation of advancing
worldwide access to drugs for legitimate medical purposes.
duction, and manufacture of, and illicit trafficking in
and use of, drugs.”53 (Emphasis added.) The INCB has,
in fact, undertaken studies and surveys on medical
availability54 and, in its annual reports, the INCB has
generally called upon nations to revise restrictive laws
that interfere with opioid availability for medical purposes and that are in excess of the Single Convention’s
requirements.
Despite its rhetorical commitment to medical availability, in its operational activities and programmes,
the INCB, along with the Secretariat that supports
its work, views its mission as primarily one of law
enforcement and drug control. Concerned that legitimate medicines can be diverted into illicit channels,
the INCB has prioritized strict regulation of opioid
analgesics in policy and practice. This has, concomitantly, relegated issues of medical availability to secondary consideration. Consequently, the INCB has
not advanced any interpretation or application of the
Single Convention in a manner that fulfills its obligation of advancing worldwide access to drugs for legitimate medical purposes.
Lessons from the Scheduling of Narcotic Drugs under
the Single Convention: A Case Study of the Neglect of
Medical Availability in International Practice
The most notable examples of the INCB’s prohibitionist bias negatively impacting legitimate availability of
pain medication for populations worldwide involve the
562

only in accordance with the schedule recommended
by WHO. This two-part review and scheduling process
affects the controls that will be placed on medicines in
each country pursuant to the Single Convention. As
the Single Convention is widely adhered to, the scheduling decisions are of tremendous importance to the
accessibility of drugs.
The scheduling process, including the rescheduling
of substances already under international control, can
have a substantial and unintended negative impact on
medical availability of drugs worldwide.55 The regulatory requirements for drugs that are scheduled or
rescheduled under the Single Convention can be tremendously burdensome and, at times, can outstrip
the capacity of poor countries. Instituting the complex
and extensive regulatory requirements mandated by
the Single Convention for a scheduled substance is
not a simple or perfunctory undertaking. Drafting
and implementing effective national drug regulation
necessitates technical skill as well as legal, financial,
and technical capacity. It is widely appreciated that
because of the regulatory burden imposed by the Single Convention, many poor states simply ban a medicine that may have important public health purposes
when the substance is scheduled or rescheduled. Consequently, it is critically important to ensuring medical availability of legitimate medicines that scheduling
decisions are based on solid medical, scientific, and
public health information.
journal of law, medicine & ethics
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In a number of recent cases involving scheduling or
rescheduling under the Single Convention, the INCB
and its Secretariat have promoted the interpretation
and application of the treaty in a manner that reflects
not only their overriding concern with law enforcement and drug diversion, but also neglect for medical availability considerations. One such case is the
recent controversy involving the medical availability
of ketamine a commonly used and essential analgesic
in many states. In its 2006 annual report, the INCB
urged countries to gather information on the abuse
of ketamine, in order to assist WHO in considering
scheduling the medication for tighter control.56 Concerned with the possible diversion of this medicine
into illicit channels, the INCB also urged national
governments reporting ketamine abuse to add the
medicine to their national lists of controlled substances.57 The INCB took this action despite having,
as described above, no legal jurisdiction in the scheduling process and knowing that scheduling can have
a severe negative impact upon availability for legitimate medical purposes.
At the 2007 annual meeting of the Commission
on Narcotic Drugs (CND), the WHO representative
stated that he was “astonished” by the INCB’s “heartless” call to states to schedule the essential medicine.58
WHO has the sole responsibility to conduct the medical and scientific evaluation of drugs and make recommendations on their scheduling to the CND. In
March 2006, a WHO Expert Panel on Drug Dependence formally evaluated ketamine and did not recommend scheduling the substance.59 According to
WHO, in resource-poor settings, ketamine can be the
only substance available for anesthesia. Populations
of many developing countries crucially depend upon
access to ketamine for surgery, and the medication
is part of WHO Guidelines for surgery in health care
settings with limited technical resources. Given that
many countries simply ban a medication subject to
scheduling or rescheduling, the INCB’s unauthorized
and ill-considered call on states to schedule ketamine,
based upon the mere possibility of abuse and without
credible medical and scientific evidence, means that
many patients in developing countries will not have
access to surgery or will have to undergo surgery fully
conscious. Notably, in the 2007 CND annual report,
the controversy surrounding ketamine and WHO’s
striking intervention was not even mentioned.60
The case of ketamine is an important example of
how greatly exaggerated concerns about drug diversion have led global drug regulatory authorities to
advance drug scheduling decisions with severe public
health consequences, without appropriately weighing the impact of scheduling on the legitimate mediglobal health law, ethics, and policy • winter 2007

cal availability of a critical medicine. There are other
such examples of the INCB’s prohibitionist bias in
the scheduling process, including buprenorphine, an
important analgesic in many developing countries.61
The case of ketamine is also an important example
of how greatly exaggerated concerns about drug diversion have led the INCB to seek to undermine the legitimate legal authority of WHO to make independent
scheduling recommendations to the CND.
As described above, WHO has the sole responsibility to conduct the medical and scientific evaluation of
drugs and make recommendations to the CND concerning the level of international control to be applied.
Under the Single Convention, WHO has an established review process for scheduling recommendations in which an Expert Committee on Drug Dependence (WHO Expert Committee) evaluates substances
for international control recommendations, pursuant
to WHO Guidelines for the WHO Review of Dependence Producing Substances for International Control
(Scheduling Guidelines).62 Following the substantive
and procedural requirements set forth in the Guidelines, the WHO Expert Committee makes a scheduling recommendation to the WHO Director-General,
who has final authority to make a scheduling recommendation to the CND.
Pursuant to the Single Convention and its constitutional mandate, WHO has broad authority to consider
all relevant scientific and public health considerations
when making a drug scheduling and rescheduling recommendation, including liability for abuse and medical availability. The Official Commentary to the Single
Convention indicates that the impact of scheduling
narcotics on medical availability should be an important and appropriate consideration during the WHO
scientific review process. The Official Commentary
to Single Convention Article 3, the treaty provision
that addresses changes in the scope of control of substances, provides that WHO has “wide discretion” in
the scheduling process and should be “guided in this
choice by the interests of public health in each case, as
it appears not only from the degree of danger which
the substance in question presents but also from the
need to make useful medicines as easily available as
may be compatible with the requirements of their control.”63 The WHO scientific review process established
under the Single Convention is designed to permit
a rigorous and evidence-based evaluation of medicines that balances risks of abuse against the benefits
obtained through legitimate use. The scientific and
public health approach to drug scheduling recommendations undertaken as part of the WHO review
process, the first step in the scheduling process, also
provides a critical counterpoint and public health bal563
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ance to the more politicized forum of the Commission
on Narcotic Drugs.
The INCB’s efforts to focus the scheduling process
exclusively upon questions of abuse by, among other
things, undermining the legal authority and responsibility of WHO to provide an evidence-based analysis
for drug-scheduling recommendations raise important concerns. The INCB Secretariat’s apparent perspective that the impact of drug scheduling on medical availability should not be a central consideration
in the scheduling process is inconsistent with the text
of the Single Convention. Furthermore, as in the case
of ketamine, the INCB’s single-minded prohibitionist perspective could result in the placement of inappropriate controls on legitimate medicines. Far from
solving a public health problem, the prohibitionist
bias of INCB and the other drug regulatory agencies is
preventing legitimate patients from being prescribed
medication that they desperately need.

Achieving Balance in Global Regulatory
Drug Policy
In their efforts to fight global drug trafficking and
abuse, the international drug regulatory agencies have
adopted a narrow view of the public health objective

ing to WHO, “The Central Principle of Balance” represents the dual imperative of preventing the abuse, trafficking, and diversion of narcotic drugs while, at the
same time, ensuring medical availability. As stated by
WHO, “When misused, opioids pose a threat to society; a system of control is necessary to prevent abuse,
trafficking, and diversion, but the system of control
is not intended to diminish the medical usefulness of
opioids, nor interfere in their legitimate medical uses
and patient care.”65
The concept of the Central Principle of Balance
should not be limited to national regulatory policies,
but should also guide the development and implementation of international drug control policies. This
article has illustrated that the current worldwide system for drug control poses important risks to global
public health. In addition, the prohibitionist bias of
the international drug regulatory agencies may also
undermine the goal of drug control by exacerbating
the problem of the diversion of licit medicine into illegal channels.
As a general matter, the risk of diversion of licit medicines into illegal traffic has not traditionally been one
of the most critical challenges in international drug
control. Although the global drug regime has been sin-

Although not technically binding, the increasing number of intergovernmental
resolutions adopted by the General Assembly and other international forums
reflects the world community’s growing recognition of the critical link between
access to essential medications and human rights. The specific reference
to the link between palliative care and human rights may reflect the
community’s emerging recognition that allowing millions to suffer
preventable excruciating pain is an affront to human dignity.
of global drug control. Consistent with the twin aims
of the Single Convention, public health in the drug
regulatory context is appropriately understood in a
broader context as encompassing efforts that both
guarantee legitimate access to pain medication for
patients in need as well as control abuse and diversion. Reconceptualizing the drug control regime and
realigning the efforts of drug regulatory organs to this
public health perspective may make an important contribution to efforts to advance pain relief worldwide.
In 1998, WHO, in cooperation with its collaborating
center at the University of Wisconsin, elaborated the
concept of the “Central Principle of Balance” in order
to guide the development of national drug regulatory
policies pursuant to the Single Convention.64 Accord564

gularly unsuccessful in curbing abuse of illicit drugs, it
has been remarkably effective in curbing production
and diversion of licit narcotic drugs,66 particularly
opioid-based analgesics. The United Nations Office
on Drugs and Crime estimates that global opium production today is 80 percent of what it was almost 100
years ago.67 As late as 2006, there were no cases of the
diversion of narcotic drugs from licit to illicit international trade.68
Recently, however, the INCB has reported an increasing problem of the diversion of licit opioid analgesics
in domestic markets, particularly in the United States
and Canada.69 The Board has recognized that overly
stringent national drug control regulations, such as
complex prescription requirements, can obstruct the
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capacity of legitimate patients to get essential pain
relief. This, in turn, is contributing to the growth of
the unregulated market in licit medicines since desperate patients turn to illicit channels to obtain pain
relief that they cannot obtain through legal sources.
To the extent that the operation of the international
control regime contributes to the problem of excessive
national drug regulation, as in the case of the scheduling of analgesics described above, the efforts of the
global drug control agencies may, in fact, be contributing to the growing problem of the diversion of licit
medication.
Using the Central Principle of Balance to advance
the dual purposes of the Single Convention is consistent with international human rights law. Access
to essential medicines, including pain medicine, is
receiving increasing recognition in the practice and
praxis of international human rights law. In the context of pandemics such as HIV/AIDS, tuberculosis,
and malaria, the United Nations General Assembly
in 2004 adopted a resolution recognizing that access
to medication is a “fundamental element for achieving progressively the full realization of the right of
everyone to the enjoyment of the highest attainable
standard of physical and mental health.”70 In this resolution, the General Assembly specifically identified a
link between pain medicine and human rights when
it called upon states to adopt legislation to safeguard
and promote effective access to “preventative, curative
or palliative pharmaceutical products.”71 (Emphasis
added.) A similar resolution was adopted in the Commission on Human Rights.72 Although not technically
binding, the increasing number of intergovernmental resolutions adopted by the General Assembly and
other international forums reflects the world community’s growing recognition of the critical link between
access to essential medications and human rights.
The specific reference to the link between palliative
care and human rights may reflect the community’s
emerging recognition that allowing millions to suffer
preventable excruciating pain is an affront to human
dignity.
Rethinking the Single Convention: Advancing Access
to Pain Medication through the Implementation of
International Law
This article has illustrated that advancing public health
and protecting human rights in the international drug
regulatory context requires policymakers to elaborate
a new and more balanced approach to global drug
control. In particular, this new approach to implementation must depart from the strict prohibitionist approach that dominates the agenda of the global
drug regulatory authorities today. Policymakers must
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articulate a comprehensive and holistic approach to
drug control that balances the dual aims of the Single
Convention: preventing abuse and ensuring medical
availability.
Reconceptualizing implementation of the Single
Convention to achieve greater balance in global drug
policy can make an important contribution towards
increasing access to pain medications. The INCB, and
the Secretariat that supports its work, are of particular importance if more effective implementation of the
treaty is to be achieved. The INCB, in particular, exists
to promote governments’ application of drug treaty
provisions.
Research over the last decade and a half by scholars of international relations and international law
clearly evidences that international institutions can
produce dramatic changes in the behavior of the states
and non-states that they seek to influence.73 In other
words, international organizations, through the operation of treaty provisions, can help make treaties work.
The INCB can undertake a number of steps pursuant
to the Single Convention to encourage and assist State
Parties in strengthening access to medicines. Most
importantly, the INCB can advance an interpretation
of the scheduling process that supports legitimate
medical access to opioid analgesics. More generally,
the INCB can encourage states to strengthen national
medical availability policies by utilizing its legal
authority to monitor and implement the dual aims of
the Convention.
It is widely appreciated that supervision of national
compliance with international norms by international
institutions can help promote rule compliance by
states. International institutions can promote national
implementation of international obligations by
enabling states to be held accountable to other states
and, at times, the wider public, thereby exercising a
form of collective community supervision.74 International monitoring and supervision of compliance with
state obligations is of primary importance to international treaty implementation in a wide range of fields,
including the environment, human rights, and arms
control.75 In contrast, the absence of any provision for
institutional review has often been recognized as a
sign that a treaty is ineffective and at risk of becoming
obsolete.76
The Single Convention incorporates several rigorous international supervisory and non-compliance
mechanisms to promote national implementation
consistent with the aims of the Convention. Notably,
these mechanisms have been widely used by the INCB
to monitor national efforts to prevent drug abuse and
trafficking, as well as to critique “harm reduction” policies favored by some states. However, the procedures
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have not been employed to monitor and promote state
action on medical availability.
Consistent with contemporary treaty practice, the
Single Convention incorporates a reporting mechanism. Most treaties today require State Parties to make
periodic reports on matters affecting the treaty. While
the extent of the obligation varies, reporting procedures generally require State Parties to submit national
reports on the measures that they have adopted and
the headway that has been made in implementing a
treaty. Pursuant to Article 18 of the Single Convention,
State Parties are required to provide such an annual
report. Parties, pursuant to Article 19, are also legally
obligated to submit other information to the Board,
including estimates of drug requirements and a host
of statistical information on the production, manufacture, use, imports, and exports of drugs.
The Board has broad authority to engage in a dialogue with states on the consistency of the measures
reported, as related to the objectives of the Single
Convention. It is also authorized to publicly disclose
state activity and to critically analyze such measures
in the annual INCB report or in other reports. Article
15 of the Single Convention empowers the INCB to
include in its reports “an analysis of the estimates and
statistical information at its disposal and, in appropriate cases, an account of the explanations if any, given
by or required of Governments, together with any
observations and recommendations which the Board
desires to make.”77 Pursuant to its mandate under the
drug control treaties, the Board also regularly selects
several countries for review, with the goal of analyzing their overall compliance with the provisions of the
drug control conventions. The findings of the review,
as well as the Board’s recommendation for remedial
action, are conveyed to the State Parties individually and are generally discussed in the annual INCB
report.
Periodic reporting of states’ performance can be an
important mechanism in assisting states to identify
and alleviate obstacles when implementing international commitments.78 Reporting functions can thus
help to raise domestic bureaucratic conscience about
treaty obligations. This regular review can provide the
basis for the elaboration of clearly stated and targeted
policies. Periodic review can also expand the community of interest by facilitating public scrutiny of governmental policy. Consequently, a periodic review process can generate domestic pressure to comply with a
treaty’s terms. In addition, a monitoring process can
open a dialogue between national officials and the
monitoring organization, thereby helping states to
understand the requirements of the treaty and to proactively identify domestic difficulties with compliance.
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Finally, a reporting process can assist State Parties in
implementing international obligations by triggering
international assistance to solve domestic problems
identified during the reporting process.
In implementing the periodic reporting procedure,
the INCB has established a highly effective reporting
process with stringent critical review of national conduct. The INCB achieves almost universal reporting
compliance by State Parties and non-parties because
the manufacture, import, export, and medical use of
opioids are determined by the Board through the estimates system. Additionally, compliance with the institutional reporting process is enhanced because control of illicit narcotics is high on the criminal justice
and political agendas of states.79 However, though the
INCB has utilized the reporting process to advance
provisions of the treaty related to drug abuse and
trafficking, the Board has not generally sought to use
the uniquely effective reporting process to encourage
states to fulfill their treaty obligation to ensure medical availability of opioid analgesics.
In order to advance implementation of drug control and trafficking under the Single Convention, the
INCB also conducts periodic missions to State Parties
in order to review the national drug control situation.
The INCB reports the results of its inspections and
recommendations made to states in its annual report,
and about 20 such missions are conducted annually.
Inspections to verify treaty compliance are generally
considered the strongest method of information gathering and supervision in the international system and
can be a powerful means to encourage rule compliance.80 The strongest examples of inspection by international agencies are in arms control. The inspection regime can be used to promote public health by
encouraging states to implement their treaty commitments on medical availability. However, as in the case
of the periodic reporting mechanisms, the inspection
procedure has not generally been conceived of or used
as a tool to advance equitable access to desperately
needed pain medication.
The Single Convention also incorporates a potent
non-compliance procedure designed to secure conformity with the terms of the treaty. Non-compliance
procedures are generally an extension of the information gathering, monitoring, and supervision processes, as they represent a stronger means of inducing
states to comply.81 Non-compliance procedures can be
understood as a soft form of dispute settlement that
can pressure errant states into rule compliance. Article 14 of the Single Convention incorporates a range
of assertive mechanisms in order to encourage noncompliant states to meet their obligations under the
Single Convention. First, the INCB has the power to
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propose consultations, request explanations, and recommend that a government modify its policies if the
Board has objective reason to believe that the “aims
of this Convention are being seriously endangered by
reason of the failure of any Party, country or territory
to carry out the provisions of this Convention.”82 The
Board can also, at its discretion, request an inspection
in the territory to assess national policies.
If the INCB finds that a government has failed to
furnish satisfactory explanations or adopt remedial
recommendations suggested by the Board, or if there
is a serious situation that needs international cooperative action, then it can widely publicize the noncompliance. In particular, the INCB can put national
behavior under a spotlight by alerting the Parties,
the Commission on Narcotic Drug, and the United
Nations Economic and Social Council. The Board also
has the right to publish a report on the matter.83
The Single Convention Article 14 non-compliance
procedure could be a powerful tool for encouraging
countries to effectively advance the treaty’s objective
of medical availability. The idea of utilizing the noncompliance procedure in cases where countries have
not fulfilled their obligation to make essential medicines available may seem farfetched, but it is a reasonable and appropriate interpretation of the text of the
provision. Article 31 of the Vienna Convention on the
Law of Treaties, the treaty on treaties, sets forth that
a “treaty shall be interpreted in good faith in accordance with the ordinary meaning to be given to the
terms of the treaty in their context and in light of
their object and purpose.”84 The context referred to
means the treaty’s preamble and annexes. Notably,
Article 14.1.a. of the Single Convention provides that
the non-compliance measures are triggered when the
Board believes that the “aims” of the Convention are
seriously endangered. As medical availability is one
of the two core aims of the Convention established by
the preamble and Article 4, the ordinary meaning of
the language and the context of the treaty supports the
interpretation.85 Clearly, the initiation of an Article 14
procedure is a very serious matter, and not all cases
justify the imposition of this process. There could be
cases requiring the procedure, however, such as when
a country has consistently neglected to address the
issue of pain relief and has failed to furnish the Board
with any reasonable explanation.
Importantly, the mere threat of an Article 14 procedure by the INCB may induce governments to take
corrective action and strengthen medical availability.
Even if the government is not directly pressured by the
threat of an Article 14 procedure, in democratic societies, the public and the media may exercise pressure
for compliance. Unfortunately, as with both reporting
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and inspections procedures, the Board has neglected
to use the non-compliance procedure of Article 14 to
induce national action to ensure opioid medication for
patients in need. Notably, the INCB has never utilized
the Article 14 non-compliance procedure in a case of
medical availability.86
Collectively, the reporting, inspection, and noncompliance procedures established under the Single Convention could be important mechanisms in
encouraging countries to honor their legal obligation
to expand medical availability of critical medicines.
Interestingly, the Single Convention stands apart from
many treaties with a strong public health component
because of the potential strength of these procedures.
Powerful implementation mechanisms, particularly
non-compliance and inspection procedures, are fairly
uncommon in the international system and rare in
treaties with a significant public health component.
The Single Convention inspection regime was established because of the strong linkage between criminal justice and drug abuse. The INCB’s failure to use
these procedures is contrary to the letter and spirit of
the Single Convention and is a wasted opportunity in
making an important impact on the global challenge
of needless human pain.
Of course, monitoring and implementation are not
the only international institutional mechanisms to
support treaty adherence by State Parties. A variety of
national factors account for compliance with international obligations, and not all violations are premeditated or purposeful. As a general matter, it is widely
recognized that the failure of states to implement
international commitments into national law and policy may reflect, to some degree, a limitation of capacity
or capability, and not a lack of political will.87
This is certainly the case with medical availability
of powerful analgesics. As described above, a lack of
technical, legal, and bureaucratic capacity characterizes the drug regulatory framework in many countries
and significantly obstructs advancing the availability
of narcotics for pain relief. Working with WHO on
its new Access to Controlled Medicines Programme
could greatly assist states in meeting their legal obligation to ensure medical availability of opioids. The
INCB and WHO could provide technical assistance to
states in implementing standards on access to opioid
medications, including strengthening national capacity to meet the regulatory requirements of the estimates system.88
Elements from other global regimes can also provide guidance in strengthening the implementation
of the Single Convention to advance medical availability of essential pain medications. One critical area
for strengthened national and international action
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is the financing and supply of opioid analgesics. As
described above, one of the key obstacles to pain control in developing countries is the lack of availability of cheap, generic forms of morphine. Innovative
approaches for addressing this public health dilemma
are urgently needed. One possible approach would
involve the collaboration of the INCB, UNODOC, and
WHO to establish a global financing mechanism that
would advance the universal availability of inexpensive generic forms of morphine. By using its purchasing power while carefully regulating availability and
quality assurance, the INCB could solve one of the key
obstacles to drug availability in poor states.
As the lead institution of the global drug regulatory
regime, the INCB has an express legal obligation to
advance the aim of the Single Convention in ensuring
medical availability. By utilizing the reporting, inspection, and non-compliance mechanisms incorporated
in the treaty, and by encouraging effective collaborations between UNODOC and WHO in providing technical and financial support to poor states, the INCB
could make an unparalleled contribution to advancing
universal availability of opioid medications. By working effectively with governments on this critical public
health and human rights concern, the INCB may be
able to address and alleviate the lack of national political commitment to effective pain control. The development of new national laws and policies on pain
control may also, over time, contribute to a broadened
understanding and acceptability of medicinal pain
control among domestic populations. In other words,
international action could trigger the implementation
of national laws and policies that may contribute to
expanding knowledge about pain medicine among
patients and providers. This process can help to create
a social climate in which pain relief is not only socially
acceptable, but also universally recognized as an integral component of good clinical practice.

Conclusion
Today we have the knowledge and the experience to
control pain and significantly diminish human suffering. The tragedy is that for most of the world’s population effective pain control is entirely unavailable. Pain
control is inexpensive, cost effective, and can be integrated into resource-poor settings. Yet the access gap
between rich and poor countries continues to widen.
The global public health and human rights challenge
is to expand awareness and action, nationally and
internationally, and to ensure equitable access to good
pain control for all legitimate patients.
This paper has recommended an alternative
approach to international drug control – one that is
consistent with the Single Convention and that seeks
568

to balance control of abuse with medical availability.
Ultimately, political commitment, particularly among
major donors to U.N. drug control efforts, will be
the most essential component of a new drug control
regime. Rethinking the Single Convention requires
collective action by a group of countries with a shared
reform agenda. Even with political support from key
states, the complexity of the issues surrounding the
pain matrix means that there is no magic policy pill
that can ensure effective medical availability of opioids. However, national and international policies
that balance concern of abuse and medical availability
are critical components of advancing pain treatment
worldwide.
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